Skip to content
Screener

MBX Biosciences, Inc. MBX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
-$159.56M-254%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.18M-33.9%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$130.96M-36.8%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$54.4M-7.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$78.24M+1,297%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$3.27B+763%
Enterprise value$3.22B+850%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210593
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Interest and other income, net3,7482,649
Net loss$(23,517)$(23,880)
Unrealized loss on marketable securities(892)(2)
Total other comprehensive loss(892)(2)
Total comprehensive loss$(24,409)$(23,882)
Net loss attributable to common stockholders$(23,517)$(23,880)
Net loss per common share, basic and diluted$(0.50)$(0.71)
Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted46,576,20433,412,386

Item 1. Financial Statements.

FAQ

What is MBX Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
MBX Biosciences, Inc. (MBX) reported comprehensive income (loss), net of tax, attributable to parent of -$24.41M in Q1 2026.
How has MBX Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
MBX Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 2.2% year-over-year, from -$23.88M to -$24.41M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on investments. It provides a more holistic view of the company's financial performance beyond traditional accounting profit. Investors use this to evaluate the total impact of all financial activities on the company's net worth.

Ask your AI about MBX Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude